Financial Daily from THE HINDU group of publications
Tuesday, Mar 30, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Mergers & Acquisitions


ABL Bio to buy partner's stake in Shantha Marine

Our Bureau

Chennai , March 29

THE Chennai-based ABL Biotechnologies Ltd will acquire the entire stake in Shantha Marine Biotechnologies Pvt Ltd, a joint venture it promoted with Shantha Biotechnics Pvt Ltd of Hyderabad.

Mr K.O. Isaac, Managing Director, ABL Biotechnologies, told newspersons on Monday that Shantha Biotechnics would exit the partnership following a recent agreement.

Either ABL or a strategic partner to be identified by ABL will acquire the 60 per cent equity held by Shantha Biotechnics. The remaining Rs 3.5-crore equity is held by ABL.

The Rs 12-crore joint venture was promoted in 2000 to culture a marine alga and extract provitamin-A, beta carotene, based on technology developed by ABL.

Shantha Marine Biotechnologies produced over 75 formulations of beta carotene-based products, which it sold to over 40 major pharmaceutical companies, he said.

To restructure the company, ABL will commercialise more products, widen its market, introduce beta carotene-fortified food products, and infuse more funds into the project through a strategic partner.

As of now, a Texas-based biotechnology company, Samudra Technologies Inc - part of the $25-million Bionexus group - is set to partner with ABL.

According to Mr Venkata S. Santhanaraman, President, Samudra, discussions are at a preliminary stage but the company is looking at bringing in about $5 million.

Samudra will take dietary supplements produced by the joint venture to markets in the US.

This move means that ABL Biotechnologies, in addition to being a research and development company, will directly get into commercialisation and marketing.

ABL has been working on extracting biochemicals from marine micro-organisms for use by the food and pharmaceutical industry.

In the pipeline are a host of anti-viral and anti-microbial products and those that can be applied in various segments like child health, diabetes, ophthalmology and dermatology, according to Mr Isaac.

Shantha Marine is in the process of introducing in the domestic and export markets beta carotene-fortified food products like jams, squashes, cooking oils and chocolates. These can be used by diabetic patients with a beneficial impact on their condition, Mr Isaac added.

More Stories on : Mergers & Acquisitions | Bio-tech & Genetics

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Tata Power Broadband to spread to Delhi, Bangalore, Pune


DaimlerChrysler's Maybach gets a few calls
KEC completes Iraq project
C-DIT bags Rs 1.25-cr deal
Glenmark declares interim dividend
Reliance concludes $250-m term loan syndication
M&M to raise $100 m
SAIL, Essar move High Court for probe into steel dumping
Bayer sues Dr Reddy's for patent infringement
Strides programme to hone staff skills
Guj Ambuja's CCB converted to equity shares
EID Parry to sell 3 units to group co
Daewoo Commercial acquisition part of global strategy: Ratan Tata
Tata Motors vows to turn Daewoo unit profitable
Groupe Chimique buys 5 pc stake in GFCL
Matrix Labs to merge 4 cos with itself
ACC picks up UTI's stake to become 100% owner of Bargarh
ABL Bio to buy partner's stake in Shantha Marine
Sundram Fasteners buys stake in Upasana Engg
Shri Shri Resorts acquires 19.11 pc in Vivo Bio Tech
ICICI Ventures takes 54 pc in Arvind Brands
Solae plans to set up production unit in India — Launches soy products in tie up with Speedway
Lupin inks pact with Allergan to market kids' drugs
Tata Power willing to put in Rs 10,000 cr in distribution, generation
Balrampur Chini rights issue likely in early May
LG India targets Rs 7,000-cr sales this fiscal
HMT Q3 loss widens



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line